2021 Universal Registration Document

5 2021 CONSOLIDATED FINANCIAL STATEMENTS Notes to the consolidated financial statements

EQUITY AND EARNINGS PER SHARE NOTE 14

Equity 14.1.

All of the Sopra Steria Group shares held by the parent company or any of its subsidiaries are recognised at their acquisition cost, deducted from consolidated equity. Dividends 14.1.3. At Sopra Steria Group’s General Meeting of 26 May 2021, the shareholders resolved to distribute an ordinary dividend of €41.1 million in respect of financial year 2020, equating to €2.0 per share. The dividend was paid on 3 June 2021 for a total of Accumulated translation reserves 14.1.4. In line with the principles described in Note 1.4.2.b, accumulated translation reserves include the gains or losses arising on translation from the functional currencies of the Group’s entities to the presentation currency as well as the currency hedging effects of net investments in foreign operations. Movements are recorded in Other comprehensive income. Accumulated translation reserves also reflect the translation effects of gains or losses on disposals of foreign operations. €40.7 million, net of the dividend on treasury shares. No dividends were paid in 2020 in respect of 2019.

The consolidated statement of changes in equity is presented on page 172. Changes in share capital 14.1.1. At 31 December 2021, Sopra Steria Group had a share capital of €20,547,701, the same as at 31 December 2020. It is represented by 20,547,701 fully paid-up shares with a par value of €1 each. Transactions in treasury shares 14.1.2. At 31 December 2021, the value of treasury shares recognised as a deduction from consolidated equity was €51.6 million, consisting of 334,152 shares, including 254,178 shares held by UK trusts falling within the consolidation scope and 79,974 shares acquired by Sopra Steria Group, 4,805 of which were acquired under the liquidity agreement and the rest of which were acquired to make any potential share-based payments. This value also includes €9.8 million relating to the Group’s commitment to acquire shares on the market for its free performance share plans (see Note 5.4.1).

At 31 December 2021, accumulated translation reserves by currency were as follows:

31/12/2021

31/12/2020

(in millions of euros)

Swiss franc

10.4 -60.6

8.1

Pound sterling Indian rupee

-83.2

-2.5

-8.2

Norwegian krone

-18.6

-23.6

Polish zloty

-0.6 -0.1 -3.6 -0.1

-0.6

Singapore dollar Tunisian dinar

0.1

-3.6

US dollar

0.4 1.8

Other currencies

7.3

ACCUMULATED TRANSLATION RESERVES (ATTRIBUTABLE TO THE GROUP)

-68.4

-108.9

The Group has granted the Cabinet Office a put option to sell the shares it holds in SSCL. Due to the accounting treatment of the put option granted in respect of SSCL shares, the amount of non-controlling interests on the balance sheet mainly relates to the UK Department of Health’s share in the net assets of NHS SBS (€35.7 million), and the share of the German banking network Sparda’s cooperative banks in Sopra Financial Technology GmbH (€13.3 million). In the income statement, amounts attributable to non-controlling interests mainly comprised €7.0 million for SSCL, €4.0 million for NHS SBS and -€5.2 million for Sopra Financial Technology GmbH.

The “Other currencies” category mainly includes the accumulated translation reserves of associates, and chiefly Axway Software, in the amount of €7.9 million (€1.7 million at 31 December 2020). Non-controlling interests 14.1.5. The contributions to the income statement and balance sheet of entities in which there are non-controlling interests mainly come from joint ventures formed with the UK authorities in the United Kingdom: NHS SBS, 50%-owned by the UK Department of Health, and SSCL, 25%-owned by the Cabinet Office. The Group has 50% and 75% control, respectively. They also relate to Sopra Financial Technology GmbH, acquired in 2019.

225

SOPRA STERIA UNIVERSAL REGISTRATION DOCUMENT 2021